Low platelet counts and low CD4/CD8 ratios at apheresis increase the risk of CAR T-cell manufacturing failure in myeloma

This publication has 20 references indexed in Scilit:

• Risk factors for CAR‐T cell manufacturing failure among DLBCL patients: A nationwide survey in Japan
  British Journal of Haematology, 2023
• Allogeneic BCMA-targeting CAR T cells in relapsed/refractory multiple myeloma: phase 1 UNIVERSAL trial interim results
  Nature Medicine, 2023
• Allogeneic Anti-BCMA CAR T Cells Are Superior to Multiple Myeloma-derived CAR T Cells in Preclinical Studies and May Be Combined with Gamma Secretase Inhibitors
  Cancer Research Communications, 2022
• Ciltacabtagene autoleucel, a B-cell maturation antigen-directed chimeric antigen receptor T-cell therapy in patients with relapsed or refractory multiple myeloma (CARTITUDE-1): a phase 1b/2 open-label study
  The Lancet, 2021
• Idecabtagene Vicleucel in Relapsed and Refractory Multiple Myeloma
  New England Journal of Medicine, 2021
• Wishing on a CAR: Understanding the Scope of Intrinsic T-cell Deficits in Patients with Cancer
  Cancer Discovery, 2019
• International Myeloma Working Group consensus criteria for response and minimal residual disease assessment in multiple myeloma
  The Lancet Oncology, 2016
• CD19 CAR–T cells of defined CD4+:CD8+ composition in adult B cell ALL patients
  Journal of Clinical Investigation, 2016
• Early memory phenotypes drive T cell proliferation in patients with pediatric malignancies
  Science Translational Medicine, 2016
• Chimeric antigen receptor-modified T cells derived from defined CD8+ and CD4+ subsets confer superior antitumor reactivity in vivo
  Leukemia, 2015